Cytomedix, Inc. (OTCBB:CMXI) (the "Company" or "Cytomedix") today announced that the Company has been issued a CE marking certification for its Angel® Whole Blood Separation System ("Angel") and its activAT® Autologous Thrombin Processing Kit ("activAT"). CE is a mandatory European marking for certain product groups to indicate conformity with the essential health and safety requirements set out in European Directives, and allows Cytomedix to freely sell and distribute its products throughout the 28 countries of the European Economic Area ("EEA").
The receipt of these certifications finalizes the transfer of control over the quality manufacture and distribution of these products in the EEA to Cytomedix in accordance with the terms of the acquisition from the Sorin Group in April 2010.
"With the acquisition of Angel and activAT, we gained an established presence in Europe for our platelet rich plasma products. The receipt of the CE mark allows us to continue to broaden our distribution network and to expand our European footprint," commented Martin P. Rosendale, Chief Executive Officer of Cytomedix.
"This CE mark designation, along with our recent ISO 13485 certification, confirms that Cytomedix has the highest manufacturing standards and systems. We remain committed to upholding these stringent requirements to provide our customers and their patients with the quality they have come to expect from Cytomedix," concluded Mr. Rosendale.
Red light therapy shown to significantly reduce blood sugar spikes, study finds